Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) EBIT (2018 - 2025)

Precision Biosciences (DTIL) has disclosed EBIT for 8 consecutive years, with $12.5 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 150.34% to $12.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$52.1 million through Dec 2025, down 99.33% year-over-year, with the annual reading at -$52.1 million for FY2025, 99.33% down from the prior year.
  • EBIT for Q4 2025 was $12.5 million at Precision Biosciences, up from -$20.7 million in the prior quarter.
  • The five-year high for EBIT was $24.1 million in Q2 2024, with the low at -$30.7 million in Q4 2021.
  • Average EBIT over 5 years is -$12.3 million, with a median of -$14.8 million recorded in 2022.
  • The sharpest move saw EBIT soared 871.68% in 2024, then tumbled 428.11% in 2025.
  • Over 5 years, EBIT stood at -$30.7 million in 2021, then skyrocketed by 60.59% to -$12.1 million in 2022, then dropped by 22.97% to -$14.9 million in 2023, then tumbled by 66.86% to -$24.8 million in 2024, then surged by 150.34% to $12.5 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at $12.5 million, -$20.7 million, and -$21.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.